Hikma to ease U.S. hydromorphone shortage; FDA gives nod to Terumo BCT to boost anticoagulant stocks

needles
Hikma is looking to ease the U.S. shortage of hydromorphone as the FDA gave its OK to Terumo BCT to shore up short supplies of anticoagulant solution. (Pixabay)

Generics maker Hikma is looking to ease the U.S. shortage of hydromorphone with increased production as the FDA gave its OK to Terumo BCT to shore up short supplies of anticoagulant solution.

Hikma said it released more than 5 million 2-ml vials of the injectable opioids to hospitals in June and expects to release another 3 million vials this month.

Despite the ongoing opioid crisis in America, stocks of the injectable painkiller used to treat patients in hospitals, clinics and hospices has been in short supply due to manufacturing issues. The shortage for medical institutions that rely on the drugs has been magnified by government regulations aimed at preventing the illegal sale of the addictive drugs.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Pfizer, a major manufacturer of small syringes and vials of the painkillers, has previously said it expects “full recovery date” for supplies to be reached by early 2019.

“We continue to prioritize the manufacture of opioid products affected by this shortage including fentanyl, meperidine, morphine and hydromorphone to provide hospitals and doctors with the medicines they need to best treat their patients,” Daniel Motto, EVP of Hikma’s U.S. injectables division, said in a statement.

Back in 2015, makers of injectable drugs like Hikma, Baxter and Hospira (now owned by Pfizer) came under fire for taking advantage of drug shortages to increase their prices and profits. The drugmakers defended the price hikes by pointing to the cost of upgrades at manufacturing facilities.

In a separate move to relieve drug shortages in the U.S., the FDA approved Terumo BCT’s sodium citrate 4% anticoagulant solution produced in the U.K. and commonly used during apheresis procedures to collect plasma that is then used to treat serious conditions.

Sodium citrate has been on the regulatory agency’s shortage list for more than a year. Terumo BCT said the newly approved sodium citrate will be available in the U.S. later this summer.

Suggested Articles

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.

Teva is recalling 10 more lots of losartan as blood pressure drugs tainted with suspected carcinogens continue to pop up in the U.S. supply chain.